+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 80Years
All Genders
ID06765161

Evaluating Efgartigimod Therapy for Patients with IVIG-Dependent Acetylcholine Receptor Antibody Positive Myasthenia Gravis

Led by Clinique Neuro-Outaouais · Updated on 2026-10-22

30

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating efgartigimod as a replacement for intravenous immunoglobulin IVIG therapy in patients with stable, acetylcholine receptor antibody positive myasthenia gravis who depend on regular IVIG treatments. The study aims to determine if efgartigimod is as effective or not worse than IVIG, to assess patient preference between the two treatments, and to evaluate the safety and tolerability of efgartigimod given over six months. Participants will stop IVIG one week before starting the study. Efgartigimod will be given as a one-hour intravenous infusion at a dose of 10 mgkg up to 1200 mg once weekly for four weeks, followed by a four-week break. This cycle will repeat four times until week 24. After the last treatment cycle, participants will be observed for two weeks before the study ends at week 26. Throughout the 26 weeks, participants will have weekly evaluations of their myasthenia gravis symptoms using MG-ADL and MGQOL assessments. Researchers will monitor the sustained improvement in MG-ADL scores for at least four consecutive weeks as the primary outcome. Secondary outcomes include changes in QMG scores, quality of life measures, and the number of patients continuing efgartigimod at study end. Safety and tolerability of the treatment will also be closely monitored.

CONDITIONS

Brief Title

Efgartigimod in IVIG Dependent Myasthenia Gravis Patients

Research Team

F

François Jacques, Doctor

V

Victorine Sikati Foko, Nurse

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here